Nutritional Risk and Cancer Pain as Determinants of Radiotherapy-Induced Severe Lymphocytopenia: Development and Validation of a Nutrition-Integrated Predictive Nomogram

Why It Matters

SL correlates with poorer oncologic outcomes and can limit the effectiveness of concurrent immunotherapies, making early risk identification crucial for treatment planning and supportive care.

Key Takeaways

• Nutritional risk triples odds of severe lymphocytopenia during radiotherapy.
• Moderate-to-severe cancer pain increases SL risk, especially in malnourished patients.
• Each additional radiotherapy fraction raises SL odds by ~11%.
• Nomogram integrating nutrition, pain, and fractions achieves AUC 0.77.
• Early nutrition and pain management may mitigate immune suppression in radiotherapy.

Pulse Analysis

Radiotherapy remains a cornerstone of curative cancer care, yet its collateral damage to the immune system—particularly severe lymphocytopenia—has emerged as a pivotal predictor of survival. Historically, research has centered on dosimetric variables such as total dose, irradiated volume, and fractionation schedules. However, patient‑specific factors that modulate immune resilience, like nutritional status and symptom burden, have received far less attention, creating a blind spot in risk stratification models.

The recent cohort study of 97 patients reveals that baseline nutritional risk, measured by NRS‑2002, and moderate‑to‑severe cancer pain independently amplify the likelihood of SL. Patients with a nutritional risk score of three or higher faced a 3.5‑fold increase in SL odds, while those reporting pain scores of four or above experienced a 3.8‑fold rise. Importantly, the interaction analysis suggests that pain exerts a disproportionately harmful effect among the nutritionally compromised, underscoring the synergistic nature of these vulnerabilities. By integrating these variables with the number of radiotherapy fractions, the authors constructed a nomogram that achieved a respectable AUC of 0.77, offering clinicians a practical, bedside tool for early identification of high‑risk individuals.

The implications extend beyond immediate toxicity management. As combination regimens pairing radiotherapy with immunotherapy become standard, preserving lymphocyte counts is essential to maintain synergistic anti‑tumor immunity. The nomogram can guide proactive measures—intensive dietary counseling, oral nutritional supplements, and optimized analgesic protocols—to blunt immune decline before it compromises therapeutic efficacy. Future work should validate the model across multiple institutions, incorporate detailed dosimetric data, and explore biomarkers such as lymphocyte subsets. Embedding such predictive analytics into multidisciplinary tumor boards could transform supportive care from reactive to preventive, ultimately improving survival and quality of life for cancer patients.